SAB Biotherapeutics’ DiversitAb novel drug development platform creates targeted fully human multi-epitope binding immunoglobulins (polyclonal antibodies) without the need for human donors. Its ...
Efforts to contain the spread of SARS-CoV-2 may benefit from a new analytical tool developed by a team led by biologists at Boston College, who report their computer simulation of molecular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback